Radiomic Features of ¹⁸F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes

Table 2

Characteristics of the training and validation cohorts.

	Total (n = 65)	Training (n = 49)	Validation (n = 16)
Sex				0.596
Male	45 (69.2%)	34 (69.4%)	11 (68.8%)
Female	20 (30.8%)	15 (30.6%)	5 (31.3%)
Age, median (range)	29.0 (8–72)	29 (8–72)	30 (16–54)	0.703
Ann Arbor stage				0.585
I-II	36 (55.4%)	27 (55.1%)	9 (56.3%)
III-IV	29 (44.6%)	22 (44.9%)	7 (43.8%)
Bulky disease				0.678
>10 cm	9 (13.8%)	6 (12.2%)	3 (18.8%)
<10 cm	56 (86.2%)	43 (87.8%)	13 (81.3%)
BM				0.612
Yes	9 (13.8%)	7 (14.3%)	2 (12.5%)
No	56 (86.2%)	42 (85.7%)	14 (87.5%)
Extranodal sites				0.495
Yes	25 (38.5%)	20 (40.8%)	5 (31.3%)
No	40 (61.5%)	29 (59.2%)	11 (68.8%)
B symptoms				0.389
Yes	22 (33.8%)	18 (36.7%)	4 (25.0%)
No	43 (66.2%)	31 (63.3%)	12 (75.0%)
Chemotherapy with IFRT				0.565
Yes	4 (6.2%)	4 (8.2%)	0 (0.0%)
No	61 (93.8%)	45 (91.8%)	16 (100.0%)

LDH, lactate dehydrogenase, BM, bone marrow; IFRT, involved-field radiation therapy.